Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection | Zendy

Jinkai Wan | Zendy; Shenghui Xing | Zendy; Longfei Ding | Zendy; Yongheng Wang | Zendy; Chenjian Gu | Zendy; Yanling Wu | Zendy; Bowen Rong | Zendy; Cheng Li | Zendy; Siqing Wang | Zendy; Kun Chen | Zendy; Chenxi He | Zendy; Dandan Zhu | Zendy; Songhua Yuan | Zendy; Chengli Qiu | Zendy; Chen Zhao | Zendy; Lei Nie | Zendy; Zhangzhao Gao | Zendy; Jingyu Jiao | Zendy; Xiaoyan Zhang | Zendy; Xiangxi Wang | Zendy; Tianlei Ying | Zendy; Haibin Wang | Zendy; Youhua Xie | Zendy; Yanan Lu | Zendy; Jianqing Xu | Zendy; Fei Lan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Author(s) -

Jinkai Wan,

Shenghui Xing,

Longfei Ding,

Yongheng Wang,

Chenjian Gu,

Yanling Wu,

Bowen Rong,

Cheng Li,

Siqing Wang,

Kun Chen,

Chenxi He,

Dandan Zhu,

Songhua Yuan,

Chengli Qiu,

Chen Zhao,

Lei Nie,

Zhangzhao Gao,

Jingyu Jiao,

Xiaoyan Zhang,

Xiangxi Wang,

Tianlei Ying,

Haibin Wang,

Youhua Xie,

Yanan Lu,

Jianqing Xu,

Fei Lan

Publication year - 2020

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2020.107918

Subject(s) - epitope , antibody , monoclonal antibody , virology , neutralizing antibody , covid-19 , antigen , ic50 , epitope mapping , conformational epitope , chemistry , biology , immunology , medicine , disease , in vitro , infectious disease (medical specialty) , biochemistry , pathology

Highlights • 11 neutralizing antibodies against SARS-CoV-2 target three main epitopes on RBD • Epitope-A antibody 414-1 shows neutralizing IC50 at 1.75 nM • Epitope-B antibody 553-15 can enhance the neutralizing abilities of other antibodies • One neutralizing antibody, 515-5, can cross neutralize SARS-CoV pseudovirus Summary Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than 1,000 memory B cells specific to SARS-CoV-2 S1 or its RBD (receptor binding domain) and obtain 729 paired heavy- and light-chain fragments. Among these, 178 antibodies test positive for antigen binding, and the majority of the top 17 binders with EC50 below 1 nM are RBD binders. Furthermore, we identify 11 neutralizing antibodies, eight of which show IC50 within 10 nM, and the best one, 414-1, with IC50 of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates. Graphical Abstract Download : Download high-res image (185KB) Download : Download full-size image

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research